About Us

Image-about us
Generated with Avocode. Rectangle

Our Vision

The vision of NETRIS Pharma is to provide novel therapeutic solutions to patients suffering from cancer. We focus on innovative drugs that effectively restore cancer cell death, limit cancer cell plasticity, and alleviate resistance to current antiproliferative treatments such as chemotherapy, targeted therapy, and immunotherapy. The company leverages more than 20 years of research and unique understanding of the mode-of-action of Netrin-1 and its receptor UNC5H within the Dependence Receptor family.

Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI

At the Core of Clinical Excellence

The company is located in Lyon (France) within the Léon Bérard Comprehensive Cancer Center. First spin-off of the Center, the Company benefits from a unique research and clinical environment for its development. NETRIS Pharma is Partner of several “Investissements d’Avenir” programs such as the “Laboratory of excellence” DEVweCAN, the Convergence Institute PLASCAN, the RHU DepGyn and the EIC Accelerator. The Company also internationally collaborates with  world-renowned Institutions and Pharmaceutical and industrial Companies.

Our Impact

NETRIS Pharma is focused on delivering superior clinical benefit to patients not responding well to anti-proliferative therapies. NETRIS Pharma is providing safer treatments to patients by developing new drugs targeting moieties, that are only expressed by the tumor. NETRIS Pharma organizes or strongly contributes  to scientific conferences dedicated to cancer cell resistance mecanisms and actively welcome motivated PhD scientist.


Our Team

Our team combines complementary experience in fundamental and translational research, clinical development and corporate developments.


logo Nature article

NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology

* Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. * Paired biopsies, pre-and-on NP137 treatment, highlight a statistically significant reduction of tumor epithelial-to-mesenchymal transition. * Netrin-1 blockade with NP137, is confirmed as a clinical strategy to alleviate resistance to standard treatments, in multiple clinical indications, including EC.

Reading : 15 min
Bio Boston 2023

NETRIS Pharma attending the Bio International Convention in Boston (June 5-8, 2023)

NETRIS Pharma, a clinical-stage immuno-oncology pharmaceutical company pioneering NETRIN-1-based drug discovery and development, is confirming today that CEO and Founder Patrick Mehlen, and CFO Christophe Guichard, will be attending the Bio International Convention taking place June 5-8, 2023, in Boston, MS. Meet with us at the Partnering booth ! For any information, please send an email to christopheguichard@netrispharma.com

Reading : 1 min

NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137

Lap-NET1 study will evaluate safety and efficacy of anti-netrin-1 antibody NP137 in combination with m_FOLFIRINOX for first line patients with Locally Advanced Pancreatic Ductal Adenocarcinoma

Reading : 5 min

Get in touch

Contact us